dinoprost and fenprostalene

To evaluate the effects of treatment at parturition with dinoprost tromethamine, fenprostalene, or oxytocin on postpartum disease and reproductive performance during the subsequent breeding season in dairy cows.. Prospective study.. 1,400 Holstein cows from 5 commercial dairies.. Cows were assigned within 2 hours after calving to serve as untreated control cows or to be treated with 1 mg of fenprostalene, SC; 25 mg of dinoprost tromethamine, IM; or 20 IU of oxytocin, IM. Cows were confined to treatment pens and monitored daily until fetal membranes were expelled. Cows with retained fetal membranes (RFM) were treated according to existing treatment protocols for the dairy, with the provision that intrauterine infusions were not allowed. All other disease conditions were recorded, and appropriate treatment was administered. Postpartum reproductive examinations were performed 28 to 56 days after parturition Breeding records were maintained for all cows until pregnancy was confirmed or the cow was removed from the herd.. Fetal membranes were retained in 12.1% of all cows, and this outcome was unaffected by treatment. Compared with cows without RFM, cows with RFM had longer intervals to first insemination (76.4 vs 82.0 days), reduced first insemination conception rates (46.8 vs 28.0%), and increased number of days not pregnant (103.2 vs 127.4 days). Farm, as a variable, significantly affected development of RFM and postpartum disease conditions as well as reproductive performance during the subsequent breeding season. Fetal membranes were retained in 12.4, 15.2, 8.7, 6.3, and 16.9% of cows on farms 1, 2, 3, 4, and 5, respectively. Mean days to first insemination varied from 64.5 days (farm 3) to 91.5 days (farm 1). Mean number of days not pregnant varied from 94.8 days (farm 3) to 15.9 days (farm 4).. Administration of prostaglandins or oxytocin at the time of calving does not reduce the incidence of RFM or improve reproductive performance. Farm management practices have the greatest impact on dairy cow performance.

Topics: Abortifacient Agents, Nonsteroidal; Animals; Breeding; Cattle; Cattle Diseases; Dinoprost; Female; Incidence; Labor, Obstetric; Oxytocics; Oxytocin; Placenta, Retained; Pregnancy; Prospective Studies; Prostaglandins F, Synthetic; Regression Analysis; Reproduction; Time Factors

Objectives of this study were to show postpartum plasma PGF2 alpha metabolite (PGFM) profile, to clarify whether endogenous PGF2 alpha plays a certain role in the uterine involution in cows with dystocia and/or retained placenta, and to examine the effects of fenprostalene, a long-acting PGF2 alpha analog, on the uterine involution and reproductive performance of the cows with abnormal puerperium. A group of 27 cows with dystocia and/or retained placenta showed a massive release of PGF2 alpha after parturition as indicated by a rise of plasma concentrations of PGFM, significantly higher than 33 cows with normal puerperium. The duration of the elevated plasma PGFM concentrations in the cows with abnormal puerperium was shorter than that of the normal cows. In cows with normal puerperium, those showing relatively longer duration of elevated plasma PGFM levels needed a shorter period for postpartum uterine involution than the cows showing a shorter duration of the PGFM elevation (P < 0.01), while no such relationship was observed in cows with abnormal puerperium. In field trials, an administration of an exogenous PGF2 alpha, fenprostalene, at 7 to 10 days (78 cows) or 14 to 28 days postpartum (74 cows) was found to be effective in facilitating uterine involution and resumption of ovarian cyclicity, and improved reproductive performance. It may be concluded that a large amount of PGF2 alpha is released for a relatively shorter period in cows after dystocia and/or retained placenta and the elevation of PGFM is not responsible for the uterine involution. The administration of the exogenous PGF2 alpha was shown to be effective at improving the postpartum reproductive performance of cows with abnormal puerperium.

Topics: Abortifacient Agents, Nonsteroidal; Animals; Cattle; Cattle Diseases; Dinoprost; Dose-Response Relationship, Drug; Dystocia; Endometritis; Female; Placenta, Retained; Postpartum Period; Pregnancy; Prostaglandins F, Synthetic; Random Allocation; Reproduction; Time Factors; Uterus

A single injection of a synthetic analogue of prostaglandin F2 alpha (fenprostalene; Syntex) on the day of calving or between days 14 and 21 after calving did not affect the calving to first service interval, the number of services per conception or the conception rate of dairy cows. In a second trial, cows calved more than 45 days were injected once weekly with prostaglandin F2 alpha (dinoprost; Upjohn) or fenprostalene until served at the first detected oestrus. The calving to first service interval and the conception rate were not affected. Following injection of either prostaglandin, the spread in the pattern of onset of oestrus and the range in the proportion of cows (75 to 98 per cent) seen in oestrus within seven days were similar. This variation in the time of onset of oestrus after the administration of prostaglandin precludes limiting oestrus detection to four or five days per week, and is a major limitation to the use of prostaglandins in breeding programmes in dairy cows.

Topics: Animals; Cattle; Dinoprost; Estrus; Female; Pregnancy; Prostaglandins F, Synthetic; Reproduction; Time Factors

The oxytocic effect of a prostaglandin F2 alpha analogue, fenprostalene, was assessed in 4 ovariectomized ewes fitted with electrodes in both uterine horns and in the cervix. In the absence of estradiol priming, significant motility changes were not elicited by fenprostalene. Conversely, when ewes were primed with 17-beta-estradiol, fenprostalene markedly increased the electrical activity in the uterus and cervix. After a single subcutaneous fenprostalene administration (5 micrograms/kg), activity values remained about twice that of the control values during 8.52 +/- 3.31 hours. When the same dosage was administered IM, similar post-injection activity values were obtained, but only during 5.88 +/- 0.72 hours. Oxytocic effects of fenprostalene were far longer than those elicited by a single IM administration of 50 micrograms of prostaglandin F2 alpha (tham salt)/kg (0.91 +/- 0.32 hours) or by a single IM administration of 1 microgram of cloprostenol/kg (1.88 +/- 0.81 hours). Using the dose-effect relationship curve obtained from the same ewes by continuous IV infusions of oxytocin (OXT), the postinjection activity values reached after a single subcutaneous administration of fenprostalene were equivalent to those of an IV infusion of OXT at an average dose of 4.09 ImU of OXT/kg/hr for 6 to 13 hours, according to the values of the particular ewe concerned. These long-lasting oxytocic properties, in addition to its luteolytic capabilities, would make fenprostalene a suitable drug for promoting effective evacuation of the uterus when required in daily veterinary practice.

Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Animals; Castration; Cervix Uteri; Cloprostenol; Dinoprost; Dose-Response Relationship, Drug; Electromyography; Female; Injections, Subcutaneous; Oxytocics; Oxytocin; Prostaglandins F; Prostaglandins F, Synthetic; Sheep; Uterine Contraction; Uterus

Topics: Animals; Blood Pressure; Bronchi; Cloprostenol; Dinoprost; Guinea Pigs; In Vitro Techniques; Muscle, Smooth; Platelet Aggregation; Prostaglandins F; Prostaglandins F, Synthetic; Rabbits; Rats; Thiophenes

A single injection of prostaglandin F2 alpha or fenprostalene administered during the luteal phase of the oestrous cycle to either post partum or post insemination anoestrous cows resulted in a similar level of efficacy as judged by breeding efficiency.

Topics: Anestrus; Animals; Breeding; Cattle; Dinoprost; Estrus; Female; Fertility; Insemination, Artificial; Postpartum Period; Pregnancy; Prostaglandins F; Prostaglandins F, Synthetic